A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine

Behavioural Pharmacology

Volumn 14, Issue 3, 2003, Pages 215-222

  Weiner, Ina ^a   Schiller, D ^a   Gaisler Salomon, I ^a   Green, A ^a   Joel, D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antidepressant drugs; Antipsychotic drugs; Forced swim test; Latent inhibition; Rat

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; FORCED SWIMMING TEST; IMMOBILIZATION; LATENT INHIBITION; MALE; NONHUMAN; RAT; STIMULUS RESPONSE;

EID: 0038687077     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200305000-00005     Document Type: Article

References (57)

1. Abraham G, Nair C, Tracy JI, Simpson GM, Josiassen RC (1997). The effects of clozapine on symptom clusters in treatment-refractory patients. J Clin Psychopharmacol 17:49-53.
2. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
3. Bakshi VP, Geyer MA (1995). Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198-201.
4. Borsini F, Nowakowska E, Samanin R (1984). Effect of repeated treatment with desipramine in the behavioral 'despair' test in rats: antagonism by 'atypical' but not 'classical' neuroleptics or antiadrenergic drugs. Life Sci 34:1171-1176.
5. Borsini F, Pulvirenti L, Samanin R (1985). Evidence of dopamine involvement in the effect of repeated treatment with various antidepressants in the behavioural 'despair' test in rats. Eur J Pharmacol 110:253-256.
6. Bourin M, Colombel MC, Redrobe JP, Nizard J, Hascoet M, Baker GB (1998). Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog Neuropsychopharmacol Biol Psychiatry 22:343-351.
7. Browne RG (1979). Effects of antidepressants and anticholinergics in a mouse 'behavioral despair' test. Eur J Pharmacol 58:331-334.
8. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995). New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
9. Couyureau E, Gosselin O, Di Scala G (2000). Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats. Psychopharmacology 150:226-232.
10. 1A receptor antagonists. Psychopharmacology 119:47-54.
11. Dunn LA, Atwater GE, Kilts CD (1993). Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology 112:315-323.
12. Gorka Z, Janus K (1985). Effects of neuroleptics displaying antidepressant activity on behavior of rats in the forced swimming test. Pharmacol Biochem Behav 23:203-206.
13. Gosselin G, Oberling P, Di Scala G (1996). Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behav Pharmacol 7:820-826.
14. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991). The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84.
15. Harrow M, Yonan CA, Sands JR, Marengo J (1994). Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 20:327-238.
16. Heinz A, Schmidt LG, Reischies FM (1994). Anhedonia in schizophrenic, depressed, or alcohol-dependent patients - neurobiological correlates. Pharmacopsychiatry 27:7-10.
17. Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, Weinberger DR (1998). Psychomotor slowing, negative symptoms and dopamine receptor availability - an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res 31:19-26.
18. Hillert A, Maier W, Wetzel H, Benkert O (1992). Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - a functional approach. Pharmacopsychiatry 25:213-217.
19. 2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol. Behav Brain Res 88:43-49.
20. Jakob A, Rochford J (1995). The effect of scute fluoxetine and buspirone administration on performance in a latent inhibition task. Soc Neurosci, Abstr 21:1228.
21. Kawashima K, Araki H, Aihara H (1986). Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim. Jpn J Pharmacol 40:199-204.
22. Kinon BJ, Lieberman JA (1996). Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2-34.
23. Loskutova LV (1998). The site of action of the serotoninergic system in the two-stage process of formation of latent inhibition in rats. Zh Vyssh Nerv Deyat 48:348.
24. Lucki I (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523-532.
25. Moran PM, Fisher JM, Hitchcock JM, Moser PC (1996). Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42-48.
26. Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33:275-307.
27. Nelson JC, Bowers MB Jr (1978). Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 35:1321-1328.
28. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116:2531-2357.
29. Noda Y, Mamiya T, Furukawa H, Nabeshima T (1997). Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 324:35-40.
30. Page ME, Detke MJ, Kirby ADLG, Lucki I (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147:62-67.
31. Papp M, Wieronska J (2000). Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 14:46-52.
32. Peters SL, Joseph MH (1993). Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 4:183-186.
33. Plasky P (1991). Antidepressant usage in schizophrenia. Schizophr Bull 17:649-657.
34. Porsolt RD, Le Pichon M, Jalfre M (1977). Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanism. J Psychopharmacol 12:348-355.
35. Porsolt RD, Anton G, Blavet N, Jalfre M (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391.
36. Redrobe JP, Bourin M, Colombel MC, Baker GB (1998). Phencyclidine-induced stereotyped behaviour and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 7:3-23.
37. Renard CE, Fiocco AJ, Clenet F, Hascoet M, Bourin M (2001). Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 159:42-50.
38. Sams-Dodd F (1996). Phencyclidine-induced stereotyped behaviour and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 7:3-23.
39. Sams-Dodd F (1997). Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8:196-215.
40. Sanchez C, Meier E (1997). Behavioral profile of SSRIs in animal models of depression, anxiety and aggression. Psychopharmacology 129:197-205.
41. Shadach E, Feldon J, Weiner I (1999). Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs. Int J Neuropsychopharmacol 2:283-291.
42. Shadach E, Gaisler I, Schiller D, Weiner I (2000). The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology 23:151-161.
43. Siris SG, van Kammen DP, Docherty JP (1978). Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 35:1368-1377.
44. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E (1988). Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 145:1532-1537.
45. Siris SG, Bermanzohn PC, Gonzalez A, Mason SE, White CV, Shuwall MA (1991). The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 27:331-335.
46. Swerdlow NR, Bakshi V, Geyer MA (1996). Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290-1299.
47. Tollefson GD, Sanger TM (1999). Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res 35:13-21.
48. Tollefson GD, Sanger TM, Beasley CM, Tran PV (1998). A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43:803-810.
49. Trimble KM, Bell R, King DJ (1998). Enhancement of latent inhibition in the rat at a high dose of clozapine. J Psychopharmacol 12:215-219.
50. Weiner I (1990). Neural substrates of latent inhibition: The switching model. Psychol Bull 108:442-461.
51. Weiner I (2003). The 'two-headed' latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (in press).
52. Weiner I, Feldon J (1987). Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 91:248-253.
53. Weiner I, Feldon J, Katz Y (1987). Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26:241-246.
54. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996). The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40:834-843.
55. Weiner I, Shadach E, Barkai R, Feldon J (1997). Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: Implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 16:42-50.
56. Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D (2000). Screening of antipsychotic drugs in animal models. Drug Dev Res 50:235-249.
57. Weiner I, Schiller D, Gaisler I (2003). Disruption and potentiation of latent inhibition by risperidone: The latent inhibition model of atypical antipsychotic action. Neuropsychopharmacology 28: 499-509.